, Tracking Stock Market Picks
Enter Symbol:
Impax Laboratories, Inc. (IPXL) [hlAlert]

up 109.48 %

Impax Laboratories, Inc. (IPXL) rated Buy with price target $28 by Canaccord Genuity

Posted on: Monday,  Jan 9, 2012  9:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on 01/09/2012, when the stock price was $20.99. Since
then, Impax Laboratories, Inc. has gained 109.48% as of 01/20/2016's recent price of $43.97.
If you would have followed this Canaccord Genuity's recommendation on IPXL, you would have gained 109.48% of your investment in 1472 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2012 9:25 AM Buy
20.99 28.00
as of 12/31/2012
1 Week up  0.44 %
1 Month up  0.73 %
3 Months down  -21.07 %
1 YTD down  -2.38 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy